Drug intelligence / Profile preview

LiposoMax

Development stage: Unknown
Lead developer: ONE Innovation Labs
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Oral

Overview

LiposoMax is a proprietary liposomal delivery technology developed by ONE Innovation Labs for use in the nutraceutical and cosmetic industries. The platform utilizes liposomal encapsulation to protect active ingredients from the harsh environment of the gastrointestinal tract, thereby improving their stability, absorption, and overall bioavailability. It is marketed as a high-quality ingredient for dietary supplements, often paired with vitamins or other bioactive compounds to enhance their efficacy.

Brand names: LiposoMax

Beyond the preview

Go deeper on LiposoMax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LiposoMax.

Explore the full profile